key: cord-1026496-gclu7zx9 authors: Yoshida, Naofumi; Iwata, Sachiyo; Ogawa, Masato; Izawa, Kazuhiro P.; Kuroda, Shunsuke; Kohsaka, Shun; Yonetsu, Taishi; Kitai, Takeshi; Torii, Sho; Sano, Takahide; Sakai, Yoshitada; Yamashita, Tomoya; Hirata, Ken-ichi; Matsue, Yuya; Matsumoto, Shingo; Node, Koichi title: Intensive Care Unit Admission for Moderate-to-Severe COVID-19 Patients With Known Cardiovascular Diseases or Their Risk Factors ― Insights From a Nationwide Japanese Cohort Study ― date: 2021-06-25 journal: Circulation reports DOI: 10.1253/circrep.cr-21-0066 sha: 81813ef6c5f45a7349be53c81a614d33e3423abf doc_id: 1026496 cord_uid: gclu7zx9 Background: The COVID-19 pandemic has challenged healthcare systems, at times overwhelming intensive care units (ICUs). We aimed to describe the length and rate of ICU admission, and explore the clinical variables influencing ICU use, for COVID-19 patients with known cardiovascular diseases or their risk factors (CVDRF). Methods and Results: A post hoc analysis was performed of 693 Japanese COVID-19 patients with CVDRF enrolled in the nationwide CLAVIS-COVID registration system between January and May 2020 (mean [±SD] age 68.3±14.9 years; 35% female); 199 patients (28.7%) required ICU management. The mean (±SD) ICU length of stay (LOS) was 19.3±18.5 days, and the rate of in-hospital death and hospital LOS were significantly higher (P<0.001) and longer (P<0.001), respectively, in the ICU than non-ICU group. Logistic regression analysis revealed that clinical variables reflecting impaired general condition (e.g., high C-reactive protein, low Glasgow Coma Scale score, SpO(2), albumin level), male sex, and previous use of β-blockers) were associated with ICU admission (all P<0.001). Notably, age was inversely associated with ICU admission, and this was particularly prominent among elderly patients (OR 0.97, 95% confidence interval 0.95–0.99; P=0.0018). Conclusions: One-third of COVID patients with CVDRF required ICU care during the first phase of the pandemic in Japan. Other than anticipated clinical variables, such as hypoxia and altered mental status, age was inversely associated with the use of the ICU, warranting further investigation. YOSHIDA N et al. tion regarding CLAVIS-COVID, are available through the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (ID: UMIN000040598). In the present study, only patients with cardiovascular diseases or their risk factors (CVDRF) were included for analysis. Cardiovascular diseases were defined as coronary artery disease, myocardial infarction, heart failure, valvular heart disease, arrhythmia, stroke or transient ischemic attack, deep vein thrombosis, pulmonary embolism, peripheral arterial disease, aortic aneurysm, aortic dissection, cardiopulmonary arrest, heart transplantation, left ventricular assist device, cardiac implantable electronic device (artificial cardiac pacemaker, implantable cardioverter defibrillator, and cardiac resynchronization therapy), pericarditis, myocarditis, congenital heart disease, and pulmonary hypertension. Risk factors were defined as diabetes, hypertension, and dyslipidemia. The main outcome of the study was to clarify the current ICU admission rates and determine the clinical variables that influence ICU admission. Secondary outcomes were to explore the associations between ICU LOS, hospital stay, and in-hospital survival rate. Baseline data, including age, sex, body mass index, smoking status, comorbidities, and laboratory tests, were collected from medical records; in the case of missing data, we specified the number of data analyzed. Hypertension was defined as a history of antihypertensive medication prescriptions, systolic blood pressure ≥140 mmHg, or diastolic blood pressure ≥90 mmHg. Diabetes was defined as a history of antidiabetic drugs prescriptions, with HbA1c levels ≥6.5%. Dyslipidemia was defined as a history of cholesterol medication, low-density lipoprotein cholesterol ≥130 mg/dL, high-density lipoprotein cholesterol <40 mg/dL for men and <50 mg/dL for women, total cholesterol ≥200 mg/dL, and triglycerides ≥150 mg/dL. Statistical analyses were performed using R version 3.1.0 (https://www.r-project.org/), JMP version 14 (SAS Institute, trol measures, as well as isolated and treated exposed and suspected cases according to international standards. COVID-19 patients develop critical manifestations, such as acute respiratory distress syndrome (ARDS), septic shock, acute kidney injury, and thromboembolism. 5, 6 These patients require intensive care unit (ICU) admission and mechanical ventilation, extracorporeal membrane oxygenation, or renal replacement therapy, along with standard therapy; 7 however, the number of critical care beds in Japan is relatively lower (7.3 beds/100,000 population) than in other countries. 8, 9 The number of ICU beds, associated staff, and equipment requirements are limiting but essential medical resources; therefore, understanding and predicting ICU bed demand provides crucial evidence for national medical policy and contingency planning. 10, 11 In this study, we investigated the current rate and length of ICU admission, the effect of ICU length of stay (LOS) on in-hospital mortality, and clinical variables that affect ICU admission. All participants were informed regarding their participation in the study using the opt-out approach. Written informed consent was not required under Japanese law due to the observational nature of the study, and the study was conducted in accordance with the principles of the Declaration of Helsinki. The study details were first approved by the Clinical Research Committee of Toho University Faculty of Medicine (No. M20253), and subsequently approved by the ethics committee of each participating hospital. This was a post hoc analysis of CLAVIS-COVID, a nationwide multicenter retrospective observational study. Details regarding the study design have been published elsewhere. 12 CLAVIS-COVID included consecutive patients with COVID-19 aged ≥20 years who were hospitalized in 1 of 49 hospitals across Japan between January and May 2020. COVID-19 was diagnosed using a positive nucleic acid amplification test for SARS-CoV-2. 13 Detailed inclusion and exclusion criteria, as well as other study informa- The mean hospital LOS among all patients was 24.2±22.9 days. The hospital LOS was significantly longer in the ICU than non-ICU group (34.2±22.9 vs. 20.2±17.5 days, respectively; P<0.001), whereas patients with an ICU LOS ≥30 days had a significantly longer hospital LOS than those who stayed in the ICU for <30 days (P<0.001). Furthermore, there was a significant correlation between ICU and hospital LOS (n=189; 10 patients with missing data; R=0.72; P<0.001). Cary, NC, USA), and GraphPad Prism version 7.0 (GraphPad Software, La Jolla, CA, USA). The Shapiro-Wilk test was used to determine whether the data were normally distributed. Results are expressed as mean ± SD for normally distributed data and as the median with interquartile range (IQR; 25th-75th percentiles) for non-normally distributed data. The significance of differences between 2 groups was evaluated using 2-tailed Student's t-tests; the χ2 test was used to compare categorical variables. To identify the strength and direction of the link between 2 parameters, Spearman's rank correlation coefficient was calculated. One-way analysis of variance (ANOVA) was used to compare the means of more than 2 groups. To analyze factors affecting ICU admission, logistic regression analysis was used to examine the association between the incidence of ICU admission and each variable. Factors theoretically related to ICU admission, such as age and sex, as well as factors with P<0.10 in univariate analysis, were simultaneously entered into a multivariate logistic regression model; we also performed analyses between age groups (<65 years old [non-elderly] vs. ≥65 years old [elderly]), as predictive factors for ICU admission may differ with age. The P value for the interaction (Pinteraction) was also calculated between elderly and non-elderly groups. For all tests, P<0.05 was considered significant. Of the 1,518 patients enrolled in CLAVIS-COVID, 693 (45.7%) with CVDRF were included in the present study (Figure 1) . The characteristics of the 693 patients are presented in Table 1 . The mean age was 68.3±14.9 years, with 275 patients <65 years of age; 35% were female. The mean body mass index was 24.3±5.1 kg/m 2 (n=580; 113 patients with missing data). More than half the patients (56%) were non-smokers (never smoked). The number of patients with hypertension, dyslipidemia, and diabetes was 513 (74%), 269 (38.8%), and 266 (38.4%), respectively. Sixty-nine (10.0%) patients had coexisting hypertension, dyslipidemia, and diabetes. Ninety-three patients (13.4%) experienced cardiopulmonary arrest during hospitalization. Among the 693 patients, 199 (28.7%) were treated in the ICU (Figure 2A) . Ninety-four patients (47.2%) stayed in the ICU for more than 2 weeks, whereas the mean ICU LOS was 19.3±18.5 days (n=189; 10 patients with missing data). Among the 693 patients, 108 (15.6%) died while in hospital; the rate of in-hospital death was significantly higher in the ICU group (n=59; 29.6%) than non-ICU (n=49; 9.9%) group (P<0.001). When divided into 4 groups according to age and ICU admission, in-hospital death rates were significantly (P<0.001) higher for older ICU patients ( Figure 2B) Figure 2B ). The percentage of in-hospital deaths did not differ significantly among ICU groups with different LOS (ICU LOS: 24%, 25%, 30%, 22%, and 32% for ICU LOS of 1-3, 4-7, 8-14, 15-29, and 30 days, respectively; P=0.46; Figure 2C ). Table 3) . Different clinical variables were observed between non-elderly and elderly patients; therefore, we calculated the P values for the interactions between each factor. We found that age, SpO2, and albumin showed a significant interaction with age ( Supplementary Figure) . ICU beds are in special departments that are typically reserved for the most critically ill patients, representing the highest standard level of care available. Some patients with COVID-19 may develop symptoms that require intensive care; thus, as the occupancy of ICU beds and lack of empty ICU beds are directly linked to medical collapse, analyzing the determinants of ICU admission is crucial. To summarize the main findings of this study, of the COVID-19 patients with CVDRF, 28.7% needed ICU care. The mean ICU LOS was 19.3±18.5 days, and 29.6% of patients died. Finally, male sex, as well as low GCS score, low SpO2, the previous use of β-blockers, high CRP, low albumin, and low age influenced ICU admission; age was found to be significantly prominent in the elderly the in-hospital mortality rate did not worsen with increasing ICU LOS. This may reflect a variety of systemic manifestations of COVID-19, such as pneumonia, ARDS, hypotension, and cardiac, renal, gastrointestinal, and hepatic injury, which differ widely because the expression levels of the ACE2 receptor (the entry receptor for SARS-CoV-2) in each tissue differ among patients. 16 Considering that patients who need ICU care have a significantly higher risk of in-hospital death compared with non-ICU patients, management to prevent ICU admission is important to save patients' lives, and understanding the factors that determine ICU admission is important to prevent patients from being admitted to the ICU. Unexpectedly, our results showed that low age is a predictive factor for ICU admission; however, this only patient group. A recent systematic review reported that the median ICU LOS of patients with COVID-19 was 8 days (IQR 5-13 days) within China and 7 days (IQR 4-11 days) outside of China, 10 which is shorter than the ICU LOS in the present study (median 13 days; IQR 6-28 days). Considering that our study population included only COVID-19 patients with CVDRF, these patients tended to be in a more severe condition, thus requiring longer care in the ICU. Conversely, the overall in-hospital mortality rate estimated in the present study (15.6%) was less than that reported in previous studies from the US (~20%); 14,15 however, we observed that COVID-19 patients with CVDRF who needed ICU care had an approximate 1.5-fold higher risk of in-hospital death than non-ICU patients. Unexpectedly, YOSHIDA N et al. The study details were first approved by the Clinical Research Committee of Toho University Faculty of Medicine (No. M20253) and subsequently approved by the ethics committee of each participating hospital. The deidentified participant data will not be shared. applied to patients aged ≥65 years when considering the P value for interaction. This may be because older patients chose to withdraw from highly invasive treatment in the ICU at their own will. In addition, it is speculated that social factors, such as religion, family composition, or income, may be involved in this "age paradox"; however, we cannot provide a clear explanation and this aspect should be further evaluated in future studies. We also found that low albumin and SpO2 levels were independent predictors for ICU admission in all patients. It is well known that albumin is a marker of inflammation and is not solely dependent on nutritional status, and our findings are consistent with those of previous studies demonstrating that inflammatory markers strongly predict patients at risk of respiratory deterioration, 17 or that low albumin levels at admission are predictive markers of more severe disease outcomes. 18 Interestingly, both factors showed a significant interaction with age, indicating that albumin and SpO2 levels have a strong effect on ICU admission in patients aged <65 compared with ≥65 years. In summary, assessing these clinical parameters could be helpful for risk stratification and treatment strategies in patients with COVID-19. Further studies are warranted to confirm these results and determine the cut-off value to predict ICU admission for COVID-19 patients with CVDRF. Our results indicate that approximately one-third of COVID-19 patients with CVDRF require ICU care, whereas approximately one-third of these patients die in hospital. Furthermore, impaired general condition, such as low GSC score, low SpO2, high CRP, and low albumin, along with low age, male sex, and the previous use of β-blockers, were associated with ICU admission. Overcoming COVID-19 infections is an ongoing challenge. We therefore believe that the present study contributes greatly to the treatment of patients with COVID-19, as well as to important decision making designed to prevent collapse of the medical system. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention Note from the editors: Novel coronavirus (2019-nCoV) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study Clinical characteristics of coronavirus disease 2019 in China Preparing for the most critically ill patients with COVID-19: The potential role of extracorporeal membrane oxygenation Variation in critical care services across North America and Western Europe Critical care bed capacity in Asian Countries and regions COVID-19 length of hospital stay: A systematic review and data synthesis Facing Covid-19 in Italy: Ethics, logistics, and therapeutics on the epidemic's front line Clinical and biomarker profiles and prognosis of elderly patients with coronavirus disease 2019 (COVID-19) with cardiovascular diseases and/or risk factors Considerations for diagnostic COVID-19 tests Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19 Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area Extrapulmonary manifestations of COVID-19 Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 Prevalence and severity of malnutrition in hospitalized COVID-19 patients The authors acknowledge all the investigators who participated in CLAVIS-COVID, as well as the Japanese Circulation Society. This study was supported by the Japanese Circulation Society.